This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Risk Factors for Linezolid Resistance in Staphylococcus Aureus

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Brian Potoski, University of Pittsburgh
ClinicalTrials.gov Identifier:
NCT00519025
First received: August 17, 2007
Last updated: June 9, 2017
Last verified: June 2017
  Purpose
This is a retrospective chart review study. The proposed study aims to document the risk factors for quinolone resistance in bloodstream isolates of Klebsiella species. Additionally, the adequacy of empiric antibiotic therapy for Klebsiella bloodstream infections will be assessed.

Condition
Linezolid Resistance Staphylococcus Aureus

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Retrospective
Official Title: Risk Factors for Linezolid Resistance in Staphylococcus Aureus

Resource links provided by NLM:


Further study details as provided by Brian Potoski, University of Pittsburgh:

Estimated Enrollment: 360
Study Start Date: August 2007
Estimated Study Completion Date: December 2025
Estimated Primary Completion Date: December 2025 (Final data collection date for primary outcome measure)
Detailed Description:
This is a retrospective chart review study. The proposed study aims to document the risk factors for quinolone resistance in bloodstream isolates of Klebsiella species. Additionally, the adequacy of empiric antibiotic therapy for Klebsiella bloodstream infections will be assessed. This research is important because identification of risk factors may allow earlier initiation of appropriate therapy in patients infected with these bacteria. Additionally, we will identify whether horizontal spread is responsible for this increasing trend.
  Eligibility

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
linezolid resistance to staph aureus
Criteria

Inclusion Criteria:

  • patients with linezolid resistance to staphylococcus aureus

Exclusion Criteria:

  • those that don't meet entry criteria
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00519025

Locations
United States, Pennsylvania
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania, United States, 15213
Sponsors and Collaborators
University of Pittsburgh
Investigators
Principal Investigator: Brian Potoski, PharmD University of Pittsburgh
  More Information

Responsible Party: Brian Potoski, Assistant Professor, University of Pittsburgh
ClinicalTrials.gov Identifier: NCT00519025     History of Changes
Other Study ID Numbers: PRO07080006
investigator funding ( Other Identifier: UPMC )
Study First Received: August 17, 2007
Last Updated: June 9, 2017

Keywords provided by Brian Potoski, University of Pittsburgh:
Linezolid
Staphylococcus Aureus
Infections

Additional relevant MeSH terms:
Linezolid
Anti-Bacterial Agents
Anti-Infective Agents
Protein Synthesis Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action

ClinicalTrials.gov processed this record on June 22, 2017